• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Novartis's sIBM drug fails to hit primary goal in phase IIb/III trial

Novartis's sIBM drug fails to hit primary goal in phase IIb/III trial

April 21, 2016
CenterWatch Staff

MorphoSys partner Novartis has confirmed that a phase IIb/III study examining bimagrumab (BYM338) in sporadic Inclusion Body Myositis (sIBM) did not meet its primary endpoint. Data are currently being reviewed and will inform decisions on the bimagrumab development program. Ongoing clinical trials are not being discontinued at this time.

"The outcome of the phase IIb/III study with bimagrumab in sIBM is disappointing. Nevertheless, ongoing clinical trials, including those in sarcopenia and hip fracture are continuing as planned at this stage," said Dr. Marlies Sproll, chief scientific officer of MorphoSys. "Our collaboration with Novartis has produced 11 clinical programs to date with many more to come. We are looking forward to continuing to see more successful products arising from our collaboration with Novartis."

sIBM is a rare debilitating muscle disease, characterized by progressive weakness and wasting of the muscles. Over time, patients can lose the ability to walk, experience falls and injuries, lose hand function and have swallowing difficulties.

Bimagrumab (BYM338) is a novel human monoclonal antibody developed to treat pathological muscle loss and weakness. BYM338 was developed by the Novartis Institutes for Biomedical Research (NIBR), in collaboration with Morphosys, whose Human Combinatorial Antibody Library (HuCAL) was used to identify the antibody. In addition to sIBM, bimagrumab is in clinical development for hip fracture recovery and sarcopenia, a disease characterized by age-related low muscle mass and functional impairment. Bimagrumab is administered by intravenous infusion.

sIMB is a rare, progressive muscle disease characterized by weakness and wasting of the proximal muscles (core muscles, closest to the body's midline), typically the knee flexors and distal muscles (affecting muscles further on the limbs), mainly finger flexors and pharyngeal muscles (affecting swallowing). Diagnosis of sIBM is complex, and there is no single test that enables reliable diagnosis; because of this, sIBM is often misdiagnosed. The disease mostly affects people older than 50 years, and patients may become wheelchair dependent within 10 to 15 years of disease onset. There is currently no approved treatment for sIBM.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing